首页 > 最新文献

Texas Heart Institute Journal最新文献

英文 中文
The 2022 American College of Cardiology Expert Consensus on the Role of Nonstatin Therapies: An Expert-Guided Tour. 2022年美国心脏病学会关于非他汀类药物治疗作用的专家共识:专家指导之旅。
IF 0.9 4区 医学 Pub Date : 2023-11-17 DOI: 10.14503/THIJ-23-8233
Mini G Varughese, Christie M Ballantyne
{"title":"The 2022 American College of Cardiology Expert Consensus on the Role of Nonstatin Therapies: An Expert-Guided Tour.","authors":"Mini G Varughese, Christie M Ballantyne","doi":"10.14503/THIJ-23-8233","DOIUrl":"10.14503/THIJ-23-8233","url":null,"abstract":"","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2023-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10751478/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138446594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Subcutaneous vs Transvenous Implantable Cardioverter-Defibrillators: A Brief Review of the Current Landscape. 皮下与静脉植入式心脏复律除颤器:当前形势的简要回顾。
IF 0.9 4区 医学 Pub Date : 2023-11-06 DOI: 10.14503/THIJ-23-8145
Henry C Zheng, Hamid Afshar
{"title":"Subcutaneous vs Transvenous Implantable Cardioverter-Defibrillators: A Brief Review of the Current Landscape.","authors":"Henry C Zheng, Hamid Afshar","doi":"10.14503/THIJ-23-8145","DOIUrl":"10.14503/THIJ-23-8145","url":null,"abstract":"","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2023-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10751471/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71522978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Established and Emerging Device Therapy in Heart Failure: Cardiac Contractility Modulation. 已建立和新兴的心力衰竭设备治疗:心脏收缩调节。
IF 0.9 4区 医学 Pub Date : 2023-11-02 DOI: 10.14503/THIJ-23-8184
Justin Haloot, Mihail G Chelu
{"title":"Established and Emerging Device Therapy in Heart Failure: Cardiac Contractility Modulation.","authors":"Justin Haloot, Mihail G Chelu","doi":"10.14503/THIJ-23-8184","DOIUrl":"10.14503/THIJ-23-8184","url":null,"abstract":"","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10751469/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71487672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incidence, Risk Score Performance, and In-Hospital Outcomes of Postoperative Atrial Fibrillation After Cardiac Surgery. 心脏手术后心房颤动的发生率、风险评分表现和住院结果。
IF 0.9 4区 医学 Pub Date : 2023-10-25 DOI: 10.14503/THIJ-23-8221
Matthew W Segar, Alexander Marzec, Mehdi Razavi, Karen Mullins, Joanna E Molina-Razavi, Subhasis Chatterjee, Alexis E Shafii, Jennifer R Cozart, Marc R Moon, Abdi Rasekh, Mohammad Saeed

Background: Postoperative atrial fibrillation (POAF) frequently complicates cardiac surgery. Predicting POAF can guide interventions to prevent its onset. This study assessed the incidence, risk factors, and related adverse outcomes of POAF after cardiac surgery.

Methods: A cohort of 1,606 patients undergoing cardiac surgery at a tertiary referral center was analyzed. Postoperative AF was defined based on the Society of Thoracic Surgeons' criteria: AF/atrial flutter after operating room exit that either lasted longer than 1 hour or required medical or procedural intervention. Risk factors for POAF were evaluated, and the performance of established risk scores (POAF, HATCH, COM-AF, CHA2DS2-VASc, and Society of Thoracic Surgeons risk scores) in predicting POAF was assessed using discrimination (area under the receiver operator characteristics curve) analysis. The association of POAF with secondary outcomes, including length of hospital stay, ventilator time, and discharge to rehabilitation facilities, was evaluated using adjusted linear and logistic regression models.

Results: The incidence of POAF was 32.2% (n = 517). Patients who developed POAF were older, had traditional cardiovascular risk factors and higher Society of Thoracic Surgeons risk scores, and often underwent valve surgery. The POAF risk score demonstrated the highest area under the receiver operator characteristics curve (0.65), but risk scores generally underperformed. Postoperative AF was associated with extended hospital stays, longer ventilator use, and higher likelihood of discharge to rehabilitation facilities (odds ratio, 2.30; 95% CI, 1.73-3.08).

Conclusion: This study observed a high incidence of POAF following cardiac surgery and its association with increased morbidity and resource utilization. Accurate POAF prediction remains elusive, emphasizing the need for better risk-prediction methods and tailored interventions to diminish the effect of POAF on patient outcomes.

背景:术后心房颤动(POAF)经常使心脏手术复杂化。预测POAF可以指导预防其发作的干预措施。本研究评估了心脏手术后POAF的发生率、危险因素和相关不良后果。方法:对1606名在三级转诊中心接受心脏手术的患者进行队列分析。术后房颤是根据胸科医生协会的标准定义的:手术室退出后持续时间超过1小时或需要医疗或程序干预的房颤/房扑。评估了POAF的风险因素,并使用判别(受试者-操作者特征曲线下面积)分析评估了已建立的风险评分(POAF、HATCH、COM-AF、CHA2DS2-VASc和胸科医生协会风险评分)在预测POAF中的表现。使用调整后的线性和逻辑回归模型评估POAF与次要结果的相关性,包括住院时间、呼吸机时间和出院到康复机构。结果:POAF的发生率为32.2%(n=517)。发生POAF的患者年龄较大,有传统的心血管风险因素和较高的胸科医生学会风险评分,经常接受瓣膜手术。POAF风险评分显示受试者-操作员特征曲线下的区域最高(0.65),但风险评分通常表现不佳。术后房颤与住院时间延长、呼吸机使用时间延长和出院到康复机构的可能性增加有关(比值比,2.30;95%可信区间,1.73-3.08)。结论:本研究观察到心脏手术后POAF的发病率很高,并与发病率和资源利用率的增加有关。准确的POAF预测仍然难以捉摸,强调需要更好的风险预测方法和量身定制的干预措施来减少POAF对患者预后的影响。
{"title":"Incidence, Risk Score Performance, and In-Hospital Outcomes of Postoperative Atrial Fibrillation After Cardiac Surgery.","authors":"Matthew W Segar, Alexander Marzec, Mehdi Razavi, Karen Mullins, Joanna E Molina-Razavi, Subhasis Chatterjee, Alexis E Shafii, Jennifer R Cozart, Marc R Moon, Abdi Rasekh, Mohammad Saeed","doi":"10.14503/THIJ-23-8221","DOIUrl":"10.14503/THIJ-23-8221","url":null,"abstract":"<p><strong>Background: </strong>Postoperative atrial fibrillation (POAF) frequently complicates cardiac surgery. Predicting POAF can guide interventions to prevent its onset. This study assessed the incidence, risk factors, and related adverse outcomes of POAF after cardiac surgery.</p><p><strong>Methods: </strong>A cohort of 1,606 patients undergoing cardiac surgery at a tertiary referral center was analyzed. Postoperative AF was defined based on the Society of Thoracic Surgeons' criteria: AF/atrial flutter after operating room exit that either lasted longer than 1 hour or required medical or procedural intervention. Risk factors for POAF were evaluated, and the performance of established risk scores (POAF, HATCH, COM-AF, CHA2DS2-VASc, and Society of Thoracic Surgeons risk scores) in predicting POAF was assessed using discrimination (area under the receiver operator characteristics curve) analysis. The association of POAF with secondary outcomes, including length of hospital stay, ventilator time, and discharge to rehabilitation facilities, was evaluated using adjusted linear and logistic regression models.</p><p><strong>Results: </strong>The incidence of POAF was 32.2% (n = 517). Patients who developed POAF were older, had traditional cardiovascular risk factors and higher Society of Thoracic Surgeons risk scores, and often underwent valve surgery. The POAF risk score demonstrated the highest area under the receiver operator characteristics curve (0.65), but risk scores generally underperformed. Postoperative AF was associated with extended hospital stays, longer ventilator use, and higher likelihood of discharge to rehabilitation facilities (odds ratio, 2.30; 95% CI, 1.73-3.08).</p><p><strong>Conclusion: </strong>This study observed a high incidence of POAF following cardiac surgery and its association with increased morbidity and resource utilization. Accurate POAF prediction remains elusive, emphasizing the need for better risk-prediction methods and tailored interventions to diminish the effect of POAF on patient outcomes.</p>","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2023-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658140/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54231767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimized Catheter System Demonstrates Utility for Endomyocardial Delivery of Cardiopoietic Stem Cells in Target Patients With Heart Failure. 优化的导管系统证明了在心力衰竭靶向患者心肌内输送造血干细胞的实用性。
IF 0.9 4区 医学 Pub Date : 2023-10-23 DOI: 10.14503/THIJ-23-8247
Jozef Bartunek, Andre Terzic
{"title":"Optimized Catheter System Demonstrates Utility for Endomyocardial Delivery of Cardiopoietic Stem Cells in Target Patients With Heart Failure.","authors":"Jozef Bartunek, Andre Terzic","doi":"10.14503/THIJ-23-8247","DOIUrl":"10.14503/THIJ-23-8247","url":null,"abstract":"","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2023-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658137/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50163319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The CardiAMP Cell Therapy for Heart Failure trial. CardiAMP细胞治疗心力衰竭试验。
IF 0.9 4区 医学 Pub Date : 2023-10-23 DOI: 10.14503/THIJ-23-8242
Carl J Pepine, Amish N Raval
{"title":"The CardiAMP Cell Therapy for Heart Failure trial.","authors":"Carl J Pepine, Amish N Raval","doi":"10.14503/THIJ-23-8242","DOIUrl":"10.14503/THIJ-23-8242","url":null,"abstract":"","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2023-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658138/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50163320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
ST-Segment Elevation Myocardial Infarction and Bleeding Complications in JAK2-Negative Polycythemia. JAK2阴性红细胞增多症ST段抬高心肌梗死和出血并发症。
IF 0.9 4区 医学 Pub Date : 2023-10-20 DOI: 10.14503/THIJ-23-8148
Priscilla Duran Luciano, Vanessa Sabella-Jiménez

Thrombotic and bleeding complications are major causes of morbidity and mortality in patients with polycythemia vera, who predominantly present with an alteration in the JAK2 gene. Because of their hypercoagulable state and risk of hemorrhage, patients with polycythemia vera who present with an acute myocardial infarction pose a challenge to physicians. This case report describes the presentation and treatment of a Hispanic patient with JAK2 V617F-negative primary polycythemia who developed cardiac arrest and ST-segment elevation myocardial infarction owing to complete occlusion of the left anterior descending artery as well as bleeding complications and postmyocardial pericarditis.

血栓和出血并发症是真性红细胞增多症患者发病率和死亡率的主要原因,这些患者主要表现为JAK2基因的改变。由于其高凝状态和出血风险,出现急性心肌梗死的真性红细胞增多症患者对医生构成了挑战。本病例报告描述了一名患有JAK2 V617F阴性原发性红细胞增多症的西班牙裔患者的表现和治疗,该患者因左前降支完全闭塞、出血并发症和心肌后心包炎而出现心脏骤停和ST段抬高心肌梗死。
{"title":"ST-Segment Elevation Myocardial Infarction and Bleeding Complications in JAK2-Negative Polycythemia.","authors":"Priscilla Duran Luciano, Vanessa Sabella-Jiménez","doi":"10.14503/THIJ-23-8148","DOIUrl":"10.14503/THIJ-23-8148","url":null,"abstract":"<p><p>Thrombotic and bleeding complications are major causes of morbidity and mortality in patients with polycythemia vera, who predominantly present with an alteration in the JAK2 gene. Because of their hypercoagulable state and risk of hemorrhage, patients with polycythemia vera who present with an acute myocardial infarction pose a challenge to physicians. This case report describes the presentation and treatment of a Hispanic patient with JAK2 V617F-negative primary polycythemia who developed cardiac arrest and ST-segment elevation myocardial infarction owing to complete occlusion of the left anterior descending artery as well as bleeding complications and postmyocardial pericarditis.</p>","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2023-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658142/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49693157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent Foramen Ovale-Related Hypoxemia After Bilateral Lung Transplant. 双侧肺移植后与卵相关的低氧血症。
IF 0.9 4区 医学 Pub Date : 2023-10-20 DOI: 10.14503/THIJ-23-8229
Lekhya Raavi, Pankaj Garg, Mohammad Alomari, Mostafa Ali, Ishaq Wadiwala, Magdy M El-Sayed Ahmed

A 64-year-old man with interstitial pulmonary fibrosis and a small patent foramen ovale with right-to-left shunting underwent bilateral lung transplant without closure of the patent foramen ovale. Postoperatively, the patient remained persistently hypoxemic with partial response to high-flow oxygen. Investigations revealed the presence of a large patent foramen ovale with right-to-left shunting on echocardiography and a shunt fraction of 21% on cardiac catheterization. Two months after the lung transplantation, primary surgical repair of the patent foramen ovale was performed with immediate improvement in oxygenation. Three years postoperatively, the patient remained oxygen independent.

一名患有间质性肺纤维化和小卵圆孔未闭(右向左分流)的64岁男子接受了双侧肺移植,但卵圆孔未闭合。术后,患者持续低氧血症,对高流量氧气有部分反应。研究显示,超声心动图显示存在大的卵圆孔未闭,从右向左分流,心导管插入术显示分流率为21%。肺移植两个月后,对卵圆孔未闭进行了初次手术修复,氧合立即改善。术后三年,患者仍保持吸氧状态。
{"title":"Patent Foramen Ovale-Related Hypoxemia After Bilateral Lung Transplant.","authors":"Lekhya Raavi, Pankaj Garg, Mohammad Alomari, Mostafa Ali, Ishaq Wadiwala, Magdy M El-Sayed Ahmed","doi":"10.14503/THIJ-23-8229","DOIUrl":"10.14503/THIJ-23-8229","url":null,"abstract":"<p><p>A 64-year-old man with interstitial pulmonary fibrosis and a small patent foramen ovale with right-to-left shunting underwent bilateral lung transplant without closure of the patent foramen ovale. Postoperatively, the patient remained persistently hypoxemic with partial response to high-flow oxygen. Investigations revealed the presence of a large patent foramen ovale with right-to-left shunting on echocardiography and a shunt fraction of 21% on cardiac catheterization. Two months after the lung transplantation, primary surgical repair of the patent foramen ovale was performed with immediate improvement in oxygenation. Three years postoperatively, the patient remained oxygen independent.</p>","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2023-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658146/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49693143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recovery of Lung Function After 149 Days on Extracorporeal Membrane Oxygenation for COVID-19. 体外膜氧合治疗COVID-19后149天肺功能恢复情况。
IF 0.9 4区 医学 Pub Date : 2023-10-20 DOI: 10.14503/THIJ-23-8132
Orlando R Suero, Sri Kartik Valluri, Mario H Farias-Kovac, Leo Simpson, Gabriel Loor, Diana M Guerra, Jose L Diaz-Gomez, Subhasis Chatterjee

This report highlights survival and the patient's perspective after prolonged venovenous extracorporeal membrane oxygenation (ECMO) for COVID-19-related respiratory failure. A 36-year-old man with COVID-19 presented with fever, anosmia, and hypoxia. After respiratory deterioration necessitating intubation and lung-protective ventilation, he was referred for ECMO. After 3 days of conventional venovenous ECMO, he required multiple creative cannulation configurations. Adequate sedation and recurrent bradycardia were persistent challenges. After 149 consecutive days of ECMO, he recovered native lung function and was weaned from mechanical ventilation. This represents the longest-duration ECMO support in a survivor of COVID-19 yet reported. Necessary strategies included unconventional cannulation and flexible anticoagulation.

本报告强调了COVID-19相关呼吸衰竭患者长时间静脉-静脉体外膜肺氧合(ECMO)后的生存率和患者的观点。一名患有新冠肺炎的36岁男子出现发烧、嗅觉缺失和缺氧。在呼吸系统恶化需要插管和肺部保护性通气后,他被转诊接受ECMO。经过3天的常规静脉-静脉ECMO,他需要多种创造性的插管配置。充分的镇静和复发性心动过缓是持续的挑战。在连续使用ECMO 149天后,他恢复了原有的肺功能,并停止了机械通气。这是迄今为止报道的新冠肺炎幸存者中持续时间最长的ECMO支持。必要的策略包括非常规插管和灵活的抗凝治疗。
{"title":"Recovery of Lung Function After 149 Days on Extracorporeal Membrane Oxygenation for COVID-19.","authors":"Orlando R Suero, Sri Kartik Valluri, Mario H Farias-Kovac, Leo Simpson, Gabriel Loor, Diana M Guerra, Jose L Diaz-Gomez, Subhasis Chatterjee","doi":"10.14503/THIJ-23-8132","DOIUrl":"10.14503/THIJ-23-8132","url":null,"abstract":"<p><p>This report highlights survival and the patient's perspective after prolonged venovenous extracorporeal membrane oxygenation (ECMO) for COVID-19-related respiratory failure. A 36-year-old man with COVID-19 presented with fever, anosmia, and hypoxia. After respiratory deterioration necessitating intubation and lung-protective ventilation, he was referred for ECMO. After 3 days of conventional venovenous ECMO, he required multiple creative cannulation configurations. Adequate sedation and recurrent bradycardia were persistent challenges. After 149 consecutive days of ECMO, he recovered native lung function and was weaned from mechanical ventilation. This represents the longest-duration ECMO support in a survivor of COVID-19 yet reported. Necessary strategies included unconventional cannulation and flexible anticoagulation.</p>","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2023-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658157/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50159069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Impact of Patient-Prosthesis Mismatch After Aortic Valve Replacement With a Mechanical or Biological Prosthesis. 机械或生物人工瓣膜置换术后患者人工瓣膜不匹配的临床影响。
IF 0.9 4区 医学 Pub Date : 2023-10-18 DOI: 10.14503/THIJ-22-8048
Milos Matkovic, Nemanja Aleksic, Ilija Bilbija, Ana Antic, Jelena Milin Lazovic, Marko Cubrilo, Aleksandar Milojevic, Igor Zivkovic, Svetozar Putnik

Background: Patient-prosthesis mismatch (PPM) may impair functional capacity and survival after aortic valve replacement. This study aimed to investigate the impact of PPM on long-term survival and quality of life after mechanical and biological aortic valve replacement.

Methods: This study included 595 consecutive patients who had undergone isolated aortic valve replacement. Patients were divided into 2 groups according to prosthesis type. The baseline and operative characteristics, survival rates, complications, and quality of life of the groups with and without PPM were compared for up to 6 years. The PPM calculation was performed using the effective orifice area value provided by the manufacturer divided by the patient's body surface area.

Results: The moderate to severe PPM rates were 69.8% and 3.7% after biological and mechanical prosthesis implantation, respectively. Mean survival for patients in the biological group who had PPM was statistically significantly shorter (50.2 months [95% CI, 45.2-55.3]) than for patients in the biological group without PPM (60.1 months [95% CI, 55.7-64.4]; P = .04). In the mechanical prosthesis group, there was no difference in mean survival between the subgroup with PPM (66.6 months [95% CI, 58.3-74.9]) and the subgroup without PPM (64.9 months [95% CI, 62.6-67.2]; P = .50). A quality-of-life questionnaire's scores did not differ between the groups.

Conclusion: Mismatch is common after biological valve implantation and statistically significantly affects long-term survival and quality of life. If the risk of PPM after implantation of a biological prosthesis is suspected, adopting strategies to avoid PPM at the time of surgery is warranted.

背景:患者假体不匹配(PPM)可能会损害主动脉瓣置换术后的功能能力和生存率。本研究旨在研究PPM对机械和生物主动脉瓣置换术后长期生存率和生活质量的影响。方法:本研究包括595例连续接受隔离主动脉瓣置换术的患者。根据假体类型将患者分为2组。比较有PPM组和无PPM组的基线和手术特征、生存率、并发症和生活质量长达6年。PPM计算使用制造商提供的有效孔口面积值除以患者体表面积。结果:生物和机械假体植入后,中重度PPM发生率分别为69.8%和3.7%。有PPM的生物组患者的平均生存期(50.2个月[95%CI,45.2-55.3])在统计学上显著短于无PPM的生物小组患者(60.1个月[95%CI,55.7-6.4];P=0.04),有PPM的亚组(66.6个月[95%CI,58.3-74.9])和无PPM的亚群(64.9个月[95%CI,62.6-67.2];P=.50)的平均生存率没有差异。生活质量问卷的得分在两组之间没有差异。结论:不匹配在生物瓣膜植入术后很常见,在统计学上显著影响远期生存率和生活质量。如果怀疑植入生物假体后存在PPM风险,则有必要在手术时采取避免PPM的策略。
{"title":"Clinical Impact of Patient-Prosthesis Mismatch After Aortic Valve Replacement With a Mechanical or Biological Prosthesis.","authors":"Milos Matkovic, Nemanja Aleksic, Ilija Bilbija, Ana Antic, Jelena Milin Lazovic, Marko Cubrilo, Aleksandar Milojevic, Igor Zivkovic, Svetozar Putnik","doi":"10.14503/THIJ-22-8048","DOIUrl":"10.14503/THIJ-22-8048","url":null,"abstract":"<p><strong>Background: </strong>Patient-prosthesis mismatch (PPM) may impair functional capacity and survival after aortic valve replacement. This study aimed to investigate the impact of PPM on long-term survival and quality of life after mechanical and biological aortic valve replacement.</p><p><strong>Methods: </strong>This study included 595 consecutive patients who had undergone isolated aortic valve replacement. Patients were divided into 2 groups according to prosthesis type. The baseline and operative characteristics, survival rates, complications, and quality of life of the groups with and without PPM were compared for up to 6 years. The PPM calculation was performed using the effective orifice area value provided by the manufacturer divided by the patient's body surface area.</p><p><strong>Results: </strong>The moderate to severe PPM rates were 69.8% and 3.7% after biological and mechanical prosthesis implantation, respectively. Mean survival for patients in the biological group who had PPM was statistically significantly shorter (50.2 months [95% CI, 45.2-55.3]) than for patients in the biological group without PPM (60.1 months [95% CI, 55.7-64.4]; P = .04). In the mechanical prosthesis group, there was no difference in mean survival between the subgroup with PPM (66.6 months [95% CI, 58.3-74.9]) and the subgroup without PPM (64.9 months [95% CI, 62.6-67.2]; P = .50). A quality-of-life questionnaire's scores did not differ between the groups.</p><p><strong>Conclusion: </strong>Mismatch is common after biological valve implantation and statistically significantly affects long-term survival and quality of life. If the risk of PPM after implantation of a biological prosthesis is suspected, adopting strategies to avoid PPM at the time of surgery is warranted.</p>","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2023-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658167/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49693141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Texas Heart Institute Journal
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1